Loading…
TET2 mutation in diffuse large B-cell lymphoma
Ten-eleven translocation-2 (TET2) mutation is frequently observed in myeloid malignancies, and loss-of-function of TET2 is essential for the initiation of malignant hematopoiesis. TET2 mutation presents across disease entities and was reported in lymphoid malignancies. We investigated TET2 mutations...
Saved in:
| Published in: | Journal of Clinical and Experimental Hematopathology 2016-03, Vol.56 (3), p.145-149 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | Japanese |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 149 |
| container_issue | 3 |
| container_start_page | 145 |
| container_title | Journal of Clinical and Experimental Hematopathology |
| container_volume | 56 |
| creator | Yoko Kubuki Takumi Yamaji Tomonori Hidaka Takuro Kameda Kotaro Shide Masaaki Sekine Ayako Kamiunten Keiichi Akizuki Haruko Shimoda Yuuki Tahira Kenichi Nakamura Hiroo Abe Tadashi Miike Hisayoshi Iwakiri Yoshihiro Tahara Mitsue Sueta Shojiro Yamamoto Satoru Hasuike Kenji Nagata Akira Kitanaka Kazuya Shimoda |
| description | Ten-eleven translocation-2 (TET2) mutation is frequently observed in myeloid malignancies, and loss-of-function of TET2 is essential for the initiation of malignant hematopoiesis. TET2 mutation presents across disease entities and was reported in lymphoid malignancies. We investigated TET2 mutations in 27 diffuse large B-cell lymphoma (DLBCL) patients and found a frameshift mutation in 1 case (3.7%). TET2 mutation occurred in some populations of DLBCL patients and was likely involved in the pathogenesis of their malignancies. |
| format | article |
| fullrecord | <record><control><sourceid>medicalonline</sourceid><recordid>TN_cdi_medicalonline_journals_co8lymph_2016_005603_002_0145_01492929290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>co8lymph_2016_005603_002_0145_01492929290</sourcerecordid><originalsourceid>FETCH-medicalonline_journals_co8lymph_2016_005603_002_0145_014929292903</originalsourceid><addsrcrecordid>eNqtjE0OwiAUhFloYv25AxeoeQVK6lZT9QDdE9KC0jzAlHbh7a2NRzCTzLf4MrMiWcGFzAWrYEO2KfUAQpaSZ-TY1A2jfhr16GKgLtDOWTslQ1EPD0PPeWsQKb796xm93pO11ZjM4ccduV3r5nLPvelcqzEGdMGoPk5DmL1qY7VMFYNCKoBSAp_BFBSi_NaJLQH-v6cPYSpGGQ</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>TET2 mutation in diffuse large B-cell lymphoma</title><source>PubMed Central</source><creator>Yoko Kubuki ; Takumi Yamaji ; Tomonori Hidaka ; Takuro Kameda ; Kotaro Shide ; Masaaki Sekine ; Ayako Kamiunten ; Keiichi Akizuki ; Haruko Shimoda ; Yuuki Tahira ; Kenichi Nakamura ; Hiroo Abe ; Tadashi Miike ; Hisayoshi Iwakiri ; Yoshihiro Tahara ; Mitsue Sueta ; Shojiro Yamamoto ; Satoru Hasuike ; Kenji Nagata ; Akira Kitanaka ; Kazuya Shimoda</creator><creatorcontrib>Yoko Kubuki ; Takumi Yamaji ; Tomonori Hidaka ; Takuro Kameda ; Kotaro Shide ; Masaaki Sekine ; Ayako Kamiunten ; Keiichi Akizuki ; Haruko Shimoda ; Yuuki Tahira ; Kenichi Nakamura ; Hiroo Abe ; Tadashi Miike ; Hisayoshi Iwakiri ; Yoshihiro Tahara ; Mitsue Sueta ; Shojiro Yamamoto ; Satoru Hasuike ; Kenji Nagata ; Akira Kitanaka ; Kazuya Shimoda ; Faculty of Medicine ; Oncology Unit ; Department of Transfusion and Cell Therapy ; University of Miyazaki Hospital ; University of Miyazaki ; Department of Gastroenterology and Hematology ; Liver Disease Center</creatorcontrib><description>Ten-eleven translocation-2 (TET2) mutation is frequently observed in myeloid malignancies, and loss-of-function of TET2 is essential for the initiation of malignant hematopoiesis. TET2 mutation presents across disease entities and was reported in lymphoid malignancies. We investigated TET2 mutations in 27 diffuse large B-cell lymphoma (DLBCL) patients and found a frameshift mutation in 1 case (3.7%). TET2 mutation occurred in some populations of DLBCL patients and was likely involved in the pathogenesis of their malignancies.</description><identifier>ISSN: 1346-4280</identifier><language>jpn</language><publisher>The Japanese Society for Lymphoreticular Tissue Research</publisher><ispartof>Journal of Clinical and Experimental Hematopathology, 2016-03, Vol.56 (3), p.145-149</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Yoko Kubuki</creatorcontrib><creatorcontrib>Takumi Yamaji</creatorcontrib><creatorcontrib>Tomonori Hidaka</creatorcontrib><creatorcontrib>Takuro Kameda</creatorcontrib><creatorcontrib>Kotaro Shide</creatorcontrib><creatorcontrib>Masaaki Sekine</creatorcontrib><creatorcontrib>Ayako Kamiunten</creatorcontrib><creatorcontrib>Keiichi Akizuki</creatorcontrib><creatorcontrib>Haruko Shimoda</creatorcontrib><creatorcontrib>Yuuki Tahira</creatorcontrib><creatorcontrib>Kenichi Nakamura</creatorcontrib><creatorcontrib>Hiroo Abe</creatorcontrib><creatorcontrib>Tadashi Miike</creatorcontrib><creatorcontrib>Hisayoshi Iwakiri</creatorcontrib><creatorcontrib>Yoshihiro Tahara</creatorcontrib><creatorcontrib>Mitsue Sueta</creatorcontrib><creatorcontrib>Shojiro Yamamoto</creatorcontrib><creatorcontrib>Satoru Hasuike</creatorcontrib><creatorcontrib>Kenji Nagata</creatorcontrib><creatorcontrib>Akira Kitanaka</creatorcontrib><creatorcontrib>Kazuya Shimoda</creatorcontrib><creatorcontrib>Faculty of Medicine</creatorcontrib><creatorcontrib>Oncology Unit</creatorcontrib><creatorcontrib>Department of Transfusion and Cell Therapy</creatorcontrib><creatorcontrib>University of Miyazaki Hospital</creatorcontrib><creatorcontrib>University of Miyazaki</creatorcontrib><creatorcontrib>Department of Gastroenterology and Hematology</creatorcontrib><creatorcontrib>Liver Disease Center</creatorcontrib><title>TET2 mutation in diffuse large B-cell lymphoma</title><title>Journal of Clinical and Experimental Hematopathology</title><description>Ten-eleven translocation-2 (TET2) mutation is frequently observed in myeloid malignancies, and loss-of-function of TET2 is essential for the initiation of malignant hematopoiesis. TET2 mutation presents across disease entities and was reported in lymphoid malignancies. We investigated TET2 mutations in 27 diffuse large B-cell lymphoma (DLBCL) patients and found a frameshift mutation in 1 case (3.7%). TET2 mutation occurred in some populations of DLBCL patients and was likely involved in the pathogenesis of their malignancies.</description><issn>1346-4280</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqtjE0OwiAUhFloYv25AxeoeQVK6lZT9QDdE9KC0jzAlHbh7a2NRzCTzLf4MrMiWcGFzAWrYEO2KfUAQpaSZ-TY1A2jfhr16GKgLtDOWTslQ1EPD0PPeWsQKb796xm93pO11ZjM4ccduV3r5nLPvelcqzEGdMGoPk5DmL1qY7VMFYNCKoBSAp_BFBSi_NaJLQH-v6cPYSpGGQ</recordid><startdate>20160330</startdate><enddate>20160330</enddate><creator>Yoko Kubuki</creator><creator>Takumi Yamaji</creator><creator>Tomonori Hidaka</creator><creator>Takuro Kameda</creator><creator>Kotaro Shide</creator><creator>Masaaki Sekine</creator><creator>Ayako Kamiunten</creator><creator>Keiichi Akizuki</creator><creator>Haruko Shimoda</creator><creator>Yuuki Tahira</creator><creator>Kenichi Nakamura</creator><creator>Hiroo Abe</creator><creator>Tadashi Miike</creator><creator>Hisayoshi Iwakiri</creator><creator>Yoshihiro Tahara</creator><creator>Mitsue Sueta</creator><creator>Shojiro Yamamoto</creator><creator>Satoru Hasuike</creator><creator>Kenji Nagata</creator><creator>Akira Kitanaka</creator><creator>Kazuya Shimoda</creator><general>The Japanese Society for Lymphoreticular Tissue Research</general><scope/></search><sort><creationdate>20160330</creationdate><title>TET2 mutation in diffuse large B-cell lymphoma</title><author>Yoko Kubuki ; Takumi Yamaji ; Tomonori Hidaka ; Takuro Kameda ; Kotaro Shide ; Masaaki Sekine ; Ayako Kamiunten ; Keiichi Akizuki ; Haruko Shimoda ; Yuuki Tahira ; Kenichi Nakamura ; Hiroo Abe ; Tadashi Miike ; Hisayoshi Iwakiri ; Yoshihiro Tahara ; Mitsue Sueta ; Shojiro Yamamoto ; Satoru Hasuike ; Kenji Nagata ; Akira Kitanaka ; Kazuya Shimoda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-medicalonline_journals_co8lymph_2016_005603_002_0145_014929292903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoko Kubuki</creatorcontrib><creatorcontrib>Takumi Yamaji</creatorcontrib><creatorcontrib>Tomonori Hidaka</creatorcontrib><creatorcontrib>Takuro Kameda</creatorcontrib><creatorcontrib>Kotaro Shide</creatorcontrib><creatorcontrib>Masaaki Sekine</creatorcontrib><creatorcontrib>Ayako Kamiunten</creatorcontrib><creatorcontrib>Keiichi Akizuki</creatorcontrib><creatorcontrib>Haruko Shimoda</creatorcontrib><creatorcontrib>Yuuki Tahira</creatorcontrib><creatorcontrib>Kenichi Nakamura</creatorcontrib><creatorcontrib>Hiroo Abe</creatorcontrib><creatorcontrib>Tadashi Miike</creatorcontrib><creatorcontrib>Hisayoshi Iwakiri</creatorcontrib><creatorcontrib>Yoshihiro Tahara</creatorcontrib><creatorcontrib>Mitsue Sueta</creatorcontrib><creatorcontrib>Shojiro Yamamoto</creatorcontrib><creatorcontrib>Satoru Hasuike</creatorcontrib><creatorcontrib>Kenji Nagata</creatorcontrib><creatorcontrib>Akira Kitanaka</creatorcontrib><creatorcontrib>Kazuya Shimoda</creatorcontrib><creatorcontrib>Faculty of Medicine</creatorcontrib><creatorcontrib>Oncology Unit</creatorcontrib><creatorcontrib>Department of Transfusion and Cell Therapy</creatorcontrib><creatorcontrib>University of Miyazaki Hospital</creatorcontrib><creatorcontrib>University of Miyazaki</creatorcontrib><creatorcontrib>Department of Gastroenterology and Hematology</creatorcontrib><creatorcontrib>Liver Disease Center</creatorcontrib><jtitle>Journal of Clinical and Experimental Hematopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoko Kubuki</au><au>Takumi Yamaji</au><au>Tomonori Hidaka</au><au>Takuro Kameda</au><au>Kotaro Shide</au><au>Masaaki Sekine</au><au>Ayako Kamiunten</au><au>Keiichi Akizuki</au><au>Haruko Shimoda</au><au>Yuuki Tahira</au><au>Kenichi Nakamura</au><au>Hiroo Abe</au><au>Tadashi Miike</au><au>Hisayoshi Iwakiri</au><au>Yoshihiro Tahara</au><au>Mitsue Sueta</au><au>Shojiro Yamamoto</au><au>Satoru Hasuike</au><au>Kenji Nagata</au><au>Akira Kitanaka</au><au>Kazuya Shimoda</au><aucorp>Faculty of Medicine</aucorp><aucorp>Oncology Unit</aucorp><aucorp>Department of Transfusion and Cell Therapy</aucorp><aucorp>University of Miyazaki Hospital</aucorp><aucorp>University of Miyazaki</aucorp><aucorp>Department of Gastroenterology and Hematology</aucorp><aucorp>Liver Disease Center</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TET2 mutation in diffuse large B-cell lymphoma</atitle><jtitle>Journal of Clinical and Experimental Hematopathology</jtitle><date>2016-03-30</date><risdate>2016</risdate><volume>56</volume><issue>3</issue><spage>145</spage><epage>149</epage><pages>145-149</pages><issn>1346-4280</issn><abstract>Ten-eleven translocation-2 (TET2) mutation is frequently observed in myeloid malignancies, and loss-of-function of TET2 is essential for the initiation of malignant hematopoiesis. TET2 mutation presents across disease entities and was reported in lymphoid malignancies. We investigated TET2 mutations in 27 diffuse large B-cell lymphoma (DLBCL) patients and found a frameshift mutation in 1 case (3.7%). TET2 mutation occurred in some populations of DLBCL patients and was likely involved in the pathogenesis of their malignancies.</abstract><pub>The Japanese Society for Lymphoreticular Tissue Research</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1346-4280 |
| ispartof | Journal of Clinical and Experimental Hematopathology, 2016-03, Vol.56 (3), p.145-149 |
| issn | 1346-4280 |
| language | jpn |
| recordid | cdi_medicalonline_journals_co8lymph_2016_005603_002_0145_01492929290 |
| source | PubMed Central |
| title | TET2 mutation in diffuse large B-cell lymphoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A43%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-medicalonline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TET2%20mutation%20in%20diffuse%20large%20B-cell%20lymphoma&rft.jtitle=Journal%20of%20Clinical%20and%20Experimental%20Hematopathology&rft.au=Yoko%20Kubuki&rft.aucorp=Faculty%20of%20Medicine&rft.date=2016-03-30&rft.volume=56&rft.issue=3&rft.spage=145&rft.epage=149&rft.pages=145-149&rft.issn=1346-4280&rft_id=info:doi/&rft_dat=%3Cmedicalonline%3Eco8lymph_2016_005603_002_0145_01492929290%3C/medicalonline%3E%3Cgrp_id%3Ecdi_FETCH-medicalonline_journals_co8lymph_2016_005603_002_0145_014929292903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |